Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
ACTION-1 phase 1b/3 trial of RYZ101 in somatostatin receptor subtype 2–expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Initial safety analysis.
Blocking a specific receptor is detrimental for the host and may lead to reactivation of the fungus.
Source: https://tbrnewsmedia.com/sbus-maurizio-del-poeta-expands-fungal-studies-adds-new-researchers/
Checkpoint sees this as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer as olafertinib is a third-generation epidermal growth factor receptor or EGFR inhibitor.
Chimeric antigen receptor ( rely on programming immune cells to attack cancer cells.
Source: https://investorplace.com/2023/04/3-biotech-stocks-to-buy-that-could-be-the-next-big-breakthrough/
Drug discovery and development typically begins with identifying a biological target — a gene, protein, receptor or enzyme, for example.
Source: https://venturebeat.com/ai/3-ai-trends-in-drug-discovery-that-stood-out-in-2022/
Four years later, DeGennaro and his research team published a paper in focused on IR8a — a single olfactory receptor in mosquitoes — announcing to the world that they had identified the gene mosquitoes rely on to detect people.
In this study, the researchers identified and characterized the first c-di-GMP receptor, CdgR, from the cyanobacterium Anabaena.
Source: https://phys.org/news/2023-03-cell-size-mechanism-cyanobacteria.html
LaNova said LM-305 targets G protein-coupled receptor, class C, group 5, member D (GPRC5D).
Preliminary preclinical and clinical data suggest that ONA-XR has anticancer activity by inhibiting progesterone receptor binding to chromatin, downregulating cancer stem cell mobilization, and blocking immune evasion.
The drug binds to and activates the GLP-1 receptor, stimulating secretion of the blood sugar-regulating hormone, insulin.
Source: https://medcitynews.com/2023/10/novo-nordisk-semaglutide-chronic-kidney-disease-clinical-trial/
The drug targets folate receptor alpha, a protein that is often overexpressed on the surface of ovarian cancer cells.
Source: https://medcitynews.com/2023/11/abbvie-adc-cancer-pharma/
The drug works by binding to the EGFR protein and blocking its activity, essentially locking out the receptor telling cancer cells to grow.
The GLP-1 receptor agonists also work by slowing down digestion of food and increasing the feeling of being full after eating.
These drugs belong to a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists, which mimic the action of a naturally occurring hormone in the body that regulates blood sugar levels and appetite.
The thing is that this base editing drug was developed to target the PCSK9 protein, which is important for controlling LDL-C levels through an LDL-C receptor.